Comparison of Bleeding in Patients With Nonvalvular Atrial Fibrillation Treated With Ximelagatran or Warfarin

Authors:
  • KAKarin Arneklev
    Karin Arneklev
  • SGSamuel Z. Goldhaber
    Samuel Z. Goldhaber
  • JSJohn Spandorfer
    John Spandorfer
  • FHFrank Halperin
    Frank Halperin
  • JHJay Horrow
    Jay Horrow

Abstract
In patients with nonvalvular atrial fibrillation, conventional therapy uses warfarin sodium to prevent intracardiac thrombosis and stroke.1 Ximelagatran is the first of a new class of oral anticoagulants, direct thrombin inhibitors, that bind to circulating and clot-bound thrombin.2 The Stroke Prevention Using Oral Thrombin Inhibitor in Atrial Fibrillation (SPORTIF) III and V trials found that fixed-dose ximelagatran, 36 mg twice daily, prevents stroke as well as dose-adjusted warfarin (target international normalized ratio [INR], 2.0-3.0) in patients with nonvalvular atrial fibrillation.3-5

This publication has 20 references indexed in Scilit: